

### REMARKS/ARGUMENTS

The foregoing amendments to the claims are presented to further define the present invention. Support for an atomizable composition is found on page 3, third full paragraph. Support for a dry powder is found on page 4, first full paragraph. No new matter has been added. Should the Examiner have any questions, please contact the undersigned.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080  
(862) 778-7809

  
D. Gabrielle Brouillette  
Agent for Applicants  
Reg. No. 51,384

Date: November 20, 2003